Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBSTU:UNC +0.14%96 EV-to-EBIT is 16.71 as of Aug. 20, 2026, which is 16% above its 10-year median of 14.43. GuruFocus rates STU:UNC with a GF Score™ of 96/100 and a GF Value™ of €251.73 (Modestly Undervalued). Among 368 Biotechnology companies, UCB ranks worse than 50.82% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, UCB's Enterprise Value is €43,926 Mil.
UCB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €2,628 Mil. Therefore, UCB's EV-to-EBIT for today is 16.71.
The historical rank and industry rank for UCB's EV-to-EBIT or its related term are showing as below:
STU:UNC'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.65 Med: 14.43 Max: 67.67
Current: 16.72
During the past 13 years, the highest EV-to-EBIT of UCB was 67.67. The lowest was 5.65. And the median was 14.43.
STU:UNC's EV-to-EBIT is ranked worse than 50.82% of 368
companies
in the Biotechnology industry
Industry Median: 16.63
vs STU:UNC: 16.72
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
UCB's Enterprise Value for the quarter that ended in Jun. 2026 was €52,373 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €2,628 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB EV-to-EBIT Related Terms
UCB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for UCB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:UNC vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, UCB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where UCB's EV-to-EBIT falls into.
UCB's current Enterprise Value is €43,926 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €2,628 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (STU:UNC) has a EV-to-EBIT of 16.71 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on UCB and its competitors. This is 16% above median its historical median of 14.43. Over the past decade, UCB's EV-to-EBIT has ranged from 5.65 to 67.67. According to the industry distribution chart, UCB ranks #187 out of 368 companies in the Biotechnology industry, placing it in the top 50.8%.
Is UCB's EV-to-EBIT too high?
UCB's current EV-to-EBIT of 16.71 is 16% above median its 10-year median of 14.43. Over the past 10 years, this metric has ranged from a low of 5.65 to a high of 67.67. The Biotechnology industry median EV-to-EBIT is 16.63. UCB's value of 16.71 is 0.5% above this industry median. Based on the distribution chart, UCB ranks #187 out of 368 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UCB has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #187 out of 368 companies for EV-to-EBIT. This places UCB in the lower half of its industry. The industry median EV-to-EBIT is 16.63. UCB's value of 16.71 is 0.5% above this benchmark. Historically, UCB's own EV-to-EBIT has ranged from 5.65 to 67.67 over the past decade. While the company's 10-year median is 14.43 vs. the industry median of 16.63, UCB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.63, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current EV-to-EBIT of 16.71 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on UCB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current EV-to-EBIT is 16.71, which is 16% above median its own 10-year median of 14.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Undervalued. The stock's GF Value™ is €251.73, compared to a current price of €218.00 — trading 13.4% below its estimated fair value. The current EV-to-EBIT is 16.71, which is 16% above median its 10-year median of 14.43 and 0.5% above the Biotechnology industry median of 16.63. UCB's overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For UCB (STU:UNC), the current EV-to-EBIT is 16.71 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be undervalued.
The current stock price of €218.00 is trading 13.4% below its estimated GF Value™ of €251.73.
GuruFocus considers UCB to be Modestly Undervalued.
Key valuation signals for STU:UNC:
EV-to-EBIT: 16.71 (16% above median its 10-year median of 14.43)
GF Value™: €251.73 vs. price of €218.00 (13.4% below fair value)
Industry Position: 0.5% above the Biotechnology median (#187 of 368)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
96GF Score
Get the complete analysis for STU:UNC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
